ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...

Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...

A second biosimilar to infliximab, marketed as Remicade by Johnson & Johnson, has received FDA approval. Infliximab-abda (Renflexis) was developed by Samsung Bioepis/Merck and has been approved for ...

June 13, 2006 -- The U.S. Food and Drug Administration (FDA) has approved a 2000-IU (5-mL) dose for antihemophilic factor VIII [recombinant] infusion; and an expanded indication for infliximab ...

NEW YORK (Reuters Health) - Patients with severe psoriasis previously treated with Enbrel (also known as etanercept) may respond to Remicade (also known as infliximab), a study published this month ...

HORSHAM, Pa. - Centocor, Inc. announced today that the supplemental Biologics License Application (sBLA) for REMICADE (R) (infliximab) for the treatment of pediatric Crohn's disease has been accepted ...

On October 23, 2023, Celltrion announced FDA approval for ZYMFENTRA (infliximab-dyyb), a subcutaneous formulation for maintenance therapy for patients with moderately to severely active ulcerative ...

Celltrion Healthcare is continuing to make the case for switching from intravenous to subcutaneous formulations of infliximab, with the latest data drop suggesting there may be benefits beyond ...

Switching between infliximab biosimilar SB2 and the reference product did not affect clinical disease activity or safety in IBD patients. No significant changes were observed in clinical outcomes, ...

Please provide your email address to receive an email when new articles are posted on . The switch to an infliximab biosimilar was successful in 63.5% of clinically stable patients. Most patients who ...

Crohn’s Disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract with relapsing and remitting episodes. It is a disease that progresses over time, leading to complications such as ...